Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ubrelvy
Synonyms :
ubrogepant
Class :
CGRP receptor antagonists, Antimigraine agents
Brand Name :
Ubrelvy
Synonyms :
ubrogepant
Class :
CGRP receptor antagonists, Antimigraine agents
Dosage Forms & StrengthsÂ
TabletÂ
50mgÂ
100mgÂ
Administer 50 to 100mg orally for acute migraine
If required, a second dosage may be given within two hours following the first.
Do not exceed 200mg for 24 hours.
The safety of treating more than eight migraines in 30 days has not been confirmed.
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with ubrogepant
may enhance the concentration of serum when combined with ubrogepant
may enhance the concentration of serum when combined with ubrogepant
may enhance the concentration of serum when combined with ubrogepant
may enhance the concentration of serum when combined with ubrogepant
may enhance the concentration of serum when combined with ubrogepant
may enhance the serum concentration of ubrogepant
may enhance the serum concentration of ubrogepant
may enhance the serum concentration of ubrogepant
may enhance the serum concentration of ubrogepant
may enhance the serum concentration of ubrogepant
may diminish the serum concentration of CYP3A4 Inducers
may diminish the serum concentration of CYP3A4 Inducers
ubrogepant: they may diminish the serum concentration of CYP3A4 Inducers
ubrogepant: they may diminish the serum concentration of CYP3A4 Inducers
ubrogepant: they may enhance the serum concentration of CYP3A Inhibitors
ubrogepant: they may enhance the serum concentration of CYP3A Inhibitors
ubrogepant: they may enhance the serum concentration of glycoprotein inhibitors
ubrogepant: they may enhance the serum concentration of CYP2D6 Inhibitors
ubrogepant: they may enhance the serum concentration of CYP2D6 Inhibitors
ubrogepant: they may enhance the serum concentration of CYP2D6 Inhibitors
ubrogepant: they may enhance the serum concentration of CYP2D6 Inhibitors
ubrogepant: they may enhance the serum concentration of CYP2D6 Inhibitors
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of P-glycoprotein/ABCB1 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of BCRP/ABG2 inhibitors
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may diminish the serum concentration of CYP3A4 Inducers
may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of BCRP/ABCG2 Substrates
may enhance the serum concentration of CYP3A4 Substrates
may enhance the serum concentration of P-glycoprotein/ABCB1 Substrates
may enhance the serum concentration of P-glycoprotein/ABCB1 Substrates
may enhance the serum concentration of BCRP/ABCG2 Substrates
may enhance the serum concentration of BCRP/ABCG2 Substrates
may enhance the serum concentration of P-glycoprotein/ABCB1 Substrates
may enhance the serum concentration of CYP3A4 Substrates
may diminish the serum concentration of CYP3A4 Substrates
the effect of ubrogepant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ubrogepant 
OATP1B1/1B3 inhibitors increase the concentration of asunapravir in the serum
OATP1B1/1B3 inhibitors increase the concentration of active metabolites of revefenacin in the serum
OATP1B1/1B3 inhibitors increase the concentration of taurursodiol in the serum
may diminish the serum concentration of CYP3A4 Substrates
may diminish the serum concentration of CYP3A4 Substrates
may diminish the serum concentration of CYP3A4 Substrates
may enhance the serum concentration of CYP3A4 Substrates
may diminish the serum concentration of CYP3A4 Substrates
may enhance the serum concentration of BCRP/ABCG2 Substrates
may enhance the serum concentration of P-glycoprotein/ABCB1 Substrates
may enhance the serum concentration of BCRP/ABCG2 Substrates
may diminish the serum concentration of CYP3A4 Substrates
may enhance the serum concentration of P-glycoprotein/ABCB1 Substrates
may enhance the serum concentration of CYP3A4 Substrates
the serum levels of ubrogepant may rise in conjunction with dalfopristin
the serum levels of ubrogepant may rise in conjunction with quinupristin
eltrombopag increases the concentration of OATP1B1/1B3 substrates in the serum
may increase the serum concentration of OAT1/3 substrates
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inducers decrease the concentration of ubrogepant in serum
Actions and Spectrum:Â
Mechanism of Action:Â Â
ubrogepant works by blocking the activity of the CGRP receptors, which transmit pain signals associated with migraines. CGRP is a neuropeptide released during migraine attacks and is believed to play a vital role in the pathophysiology of migraines. By inhibiting the CGRP receptors, ubrogepant helps reduce inflammation and the transmission of pain signals, relieving migraine symptoms.Â
Spectrum of ActivityÂ
It is not intended for preventive therapy or treating other types of headaches. Migraines are characterized by severe headaches often accompanied by other symptoms such as nausea, vomiting, and sensitivity to light and sound.Â
Frequency definedÂ
1-10%Â
100 mgÂ
Somnolence (3%)Â
Nausea (4%)Â
Dry mouth (2%)Â Â
50 mgÂ
Somnolence (2%)Â
Nausea (2%)Â
<1%Â
50 mgÂ
Dry mouth Â
Post-marketing reportsÂ
HypersensitivityÂ
Black box warning:Â
NoneÂ
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
ubrogepant selectively blocks the CGRP receptors, which transmit pain signals associated with migraines. CGRP is a neuropeptide released during migraine attacks and is believed to play a vital role in the pathophysiology of migraines. By inhibiting the CGRP receptors, ubrogepant helps reduce inflammation and the transmission of pain signals, relieving migraine symptoms.Â
Pharmacodynamics:Â
ubrogepant’s blockade of CGRP receptors results in the following effects:Â
Pharmacokinetics:Â
AbsorptionÂ
Peak plasma concentration is reached approximately 1.5 hours after oral administration.Â
The presence of a high-fat meal delays the peak plasma time by 2 hours and decreases the peak plasma concentration by 22%.Â
DistributionÂ
ubrogepant is moderately protein-bound, with approximately 87% bound to plasma proteins.Â
The volume of distribution (Vd) of Ubrogepant is approximately 350 L, indicating extensive distribution within the body.Â
MetabolismÂ
ubrogepant is primarily metabolized by the cytochrome P450 enzyme CYP3A4.Â
The primary metabolites of ubrogepant are glucuronide conjugate metabolites. Â
ubrogepant also exhibits weak inhibitory effects on several enzymes, including CYP2C8, CYP2C9, CYP2D6, CYP2C19, monoamine oxidase-A (MAO-A), and UDP-glucuronosyltransferase 1A1 (UGT1A1).Â
Elimination and ExcretionÂ
The half-life of ubrogepant is approximately 5-7 hours.Â
The oral clearance of ubrogepant is approximately 87 L/hr.Â
ubrogepant is primarily eliminated via hepatic metabolism, with approximately 42% excreted in the feces and 6% excreted in the urine.Â
Administration:Â
Oral administrationÂ
It can be taken with or without foodÂ
StorageÂ
It can be stored at 20 to 25°CÂ
Excursions to temperatures between 15-30ÂşC (59-86°F) are permittedÂ
Patient information leafletÂ
Generic Name: ubrogepantÂ
Why do we use ubrogepant?Â
ubrogepant is a medication used to treat migraine headaches in adults. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. Here are the primary uses of ubrogepant:Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
